Outcome markers of ART-treated HIV+ patients with early stage Kaposi's sarcoma

Owen Ngalamika; For Yue Tso; Salum Lidenge; Sody Munsaka; Danielle Shea; Charles Wood; John West

doi:10.1371/journal.pone.0235865

Outcome markers of ART-treated HIV+ patients with early stage Kaposi's sarcoma

Owen Ngalamika, For Yue Tso, Salum Lidenge, Sody Munsaka, Danielle Shea, Charles Wood, John West

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

HIV-associated/epidemic Kaposi's sarcoma (EpKS) is an AIDS-defining angio-proliferative malignancy. It can be treated with antiretroviral therapy (ART) alone or with ART plus cytotoxic chemotherapy. ART-treated EpKS can either respond or worsen upon treatment. This study aimed at identifying immunological markers of ART-treatment response. We compared responders (those with clinical EpKS tumor regression) versus poor responders (those with progressive or non-responsive EpKS). We measured plasma cytokine and chemokine levels using cytometric bead assays. Kaposi's sarcoma herpesvirus (KSHV) neutralizing antibody (nAb) responses were also quantified to test associations with treatment outcome. Interleukin (IL)-5 levels were significantly elevated in responders versus poorresponders at baseline (0.76pg/ml vs. 0.37pg/ml; p<0.01) and follow-up (0.56pg/ml vs. 0.37pg/ml; p<0.01); IL-6 was lower in responders than poor-responders at follow-up (600fg/ml vs. 4272fg/ml; p<0.05). IP-10/CxCL-10 was significantly lower at follow-up in responders versus poor-responders (187pg/ml vs. 528pg/ml; p<0.01). KSHV nAb were not significantly differential between responders and poor-responders. In conclusion, high plasma IL-5 at baseline could be a marker for ART-treated KS tumor regression, whereas increased proinflammatory cytokine IL-6, and the chemokine IP-10, associate with KS tumor progression.

Original language	English (US)
Article number	e0235865
Journal	PloS one
Volume	15
Issue number	7
DOIs	https://doi.org/10.1371/journal.pone.0235865
State	Published - Jul 2020

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Agricultural and Biological Sciences(all)
General

Access to Document

10.1371/journal.pone.0235865

Cite this

@article{b4986e4e22b647848d2db1b8bd31c18b,

title = "Outcome markers of ART-treated HIV+ patients with early stage Kaposi's sarcoma",

abstract = "HIV-associated/epidemic Kaposi's sarcoma (EpKS) is an AIDS-defining angio-proliferative malignancy. It can be treated with antiretroviral therapy (ART) alone or with ART plus cytotoxic chemotherapy. ART-treated EpKS can either respond or worsen upon treatment. This study aimed at identifying immunological markers of ART-treatment response. We compared responders (those with clinical EpKS tumor regression) versus poor responders (those with progressive or non-responsive EpKS). We measured plasma cytokine and chemokine levels using cytometric bead assays. Kaposi's sarcoma herpesvirus (KSHV) neutralizing antibody (nAb) responses were also quantified to test associations with treatment outcome. Interleukin (IL)-5 levels were significantly elevated in responders versus poorresponders at baseline (0.76pg/ml vs. 0.37pg/ml; p<0.01) and follow-up (0.56pg/ml vs. 0.37pg/ml; p<0.01); IL-6 was lower in responders than poor-responders at follow-up (600fg/ml vs. 4272fg/ml; p<0.05). IP-10/CxCL-10 was significantly lower at follow-up in responders versus poor-responders (187pg/ml vs. 528pg/ml; p<0.01). KSHV nAb were not significantly differential between responders and poor-responders. In conclusion, high plasma IL-5 at baseline could be a marker for ART-treated KS tumor regression, whereas increased proinflammatory cytokine IL-6, and the chemokine IP-10, associate with KS tumor progression.",

author = "Owen Ngalamika and Tso, {For Yue} and Salum Lidenge and Sody Munsaka and Danielle Shea and Charles Wood and John West",

note = "Publisher Copyright: {\textcopyright} 2020 Ngalamika et al.",

year = "2020",

month = jul,

doi = "10.1371/journal.pone.0235865",

language = "English (US)",

volume = "15",

journal = "PloS one",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "7",

}

TY - JOUR

T1 - Outcome markers of ART-treated HIV+ patients with early stage Kaposi's sarcoma

AU - Ngalamika, Owen

AU - Tso, For Yue

AU - Lidenge, Salum

AU - Munsaka, Sody

AU - Shea, Danielle

AU - Wood, Charles

AU - West, John

PY - 2020/7

Y1 - 2020/7

N2 - HIV-associated/epidemic Kaposi's sarcoma (EpKS) is an AIDS-defining angio-proliferative malignancy. It can be treated with antiretroviral therapy (ART) alone or with ART plus cytotoxic chemotherapy. ART-treated EpKS can either respond or worsen upon treatment. This study aimed at identifying immunological markers of ART-treatment response. We compared responders (those with clinical EpKS tumor regression) versus poor responders (those with progressive or non-responsive EpKS). We measured plasma cytokine and chemokine levels using cytometric bead assays. Kaposi's sarcoma herpesvirus (KSHV) neutralizing antibody (nAb) responses were also quantified to test associations with treatment outcome. Interleukin (IL)-5 levels were significantly elevated in responders versus poorresponders at baseline (0.76pg/ml vs. 0.37pg/ml; p<0.01) and follow-up (0.56pg/ml vs. 0.37pg/ml; p<0.01); IL-6 was lower in responders than poor-responders at follow-up (600fg/ml vs. 4272fg/ml; p<0.05). IP-10/CxCL-10 was significantly lower at follow-up in responders versus poor-responders (187pg/ml vs. 528pg/ml; p<0.01). KSHV nAb were not significantly differential between responders and poor-responders. In conclusion, high plasma IL-5 at baseline could be a marker for ART-treated KS tumor regression, whereas increased proinflammatory cytokine IL-6, and the chemokine IP-10, associate with KS tumor progression.

AB - HIV-associated/epidemic Kaposi's sarcoma (EpKS) is an AIDS-defining angio-proliferative malignancy. It can be treated with antiretroviral therapy (ART) alone or with ART plus cytotoxic chemotherapy. ART-treated EpKS can either respond or worsen upon treatment. This study aimed at identifying immunological markers of ART-treatment response. We compared responders (those with clinical EpKS tumor regression) versus poor responders (those with progressive or non-responsive EpKS). We measured plasma cytokine and chemokine levels using cytometric bead assays. Kaposi's sarcoma herpesvirus (KSHV) neutralizing antibody (nAb) responses were also quantified to test associations with treatment outcome. Interleukin (IL)-5 levels were significantly elevated in responders versus poorresponders at baseline (0.76pg/ml vs. 0.37pg/ml; p<0.01) and follow-up (0.56pg/ml vs. 0.37pg/ml; p<0.01); IL-6 was lower in responders than poor-responders at follow-up (600fg/ml vs. 4272fg/ml; p<0.05). IP-10/CxCL-10 was significantly lower at follow-up in responders versus poor-responders (187pg/ml vs. 528pg/ml; p<0.01). KSHV nAb were not significantly differential between responders and poor-responders. In conclusion, high plasma IL-5 at baseline could be a marker for ART-treated KS tumor regression, whereas increased proinflammatory cytokine IL-6, and the chemokine IP-10, associate with KS tumor progression.

UR - http://www.scopus.com/inward/record.url?scp=85087722990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087722990&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0235865

DO - 10.1371/journal.pone.0235865

M3 - Article

C2 - 32634155

AN - SCOPUS:85087722990

SN - 1932-6203

VL - 15

JO - PloS one

JF - PloS one

IS - 7

M1 - e0235865

ER -

Outcome markers of ART-treated HIV+ patients with early stage Kaposi's sarcoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this